Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia
Public ClinicalTrials.gov record NCT04998201. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Mixed Dyslipidemia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Participants who have met all protocol eligibility criteria will be randomly assigned to treatment (ARO-APOC3 or placebo) in a double-blind fashion and will be evaluated for safety and efficacy over 48 weeks. Participants will be counseled to remain on a specified diet throughout the study, as recommended by the Investigator in accordance with local standards of care. After week 48, participants will be eligible and invited to consent and continue in an open-label extension study. All placebo participants who opt to continue will switch to active drug (ARO-APOC3) during the extension study.
Study identification
- NCT ID
- NCT04998201
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 353 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 27, 2021
- Primary completion
- Feb 9, 2023
- Completion
- Aug 13, 2023
- Last update posted
- Apr 13, 2026
2021 – 2023
United States locations
- U.S. sites
- 15
- U.S. states
- 8
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site 3 | Beverly Hills | California | 90211 | — |
| Research Site 8 | Northridge | California | 91325 | — |
| Research Site 2 | Boca Raton | Florida | 33434 | — |
| Research Site 1 | Fort Lauderdale | Florida | 33308 | — |
| Research Site 14 | Miami Springs | Florida | 33166 | — |
| Research Site 5 | Pembroke Pines | Florida | 33024 | — |
| Research Site 18 | Dunwoody | Georgia | 30338 | — |
| Research Site 31 | Las Vegas | Nevada | 89121 | — |
| Research Site 17 | New Windsor | New York | 12553 | — |
| Research Site 12 | Dayton | Ohio | 45419 | — |
| Research Site 4 | Franklin | Ohio | 45005 | — |
| Research Site 7 | Greenville | South Carolina | 29607 | — |
| Research Site 6 | Houston | Texas | 77002 | — |
| Research Site 32 | Houston | Texas | 77030 | — |
| Research Site 13 | San Antonio | Texas | 78249 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 15 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04998201, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 13, 2026 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04998201 live on ClinicalTrials.gov.